scholarly journals Retraction Notice to: circRASSF2 Acts as ceRNA and Promotes Papillary Thyroid Carcinoma Progression through miR-1178/TLR4 Signaling Pathway

2021 ◽  
Vol 26 ◽  
pp. 1199
Author(s):  
Guojun Wu ◽  
Wenhong Zhou ◽  
Xiaona Lin ◽  
Yongjie Sun ◽  
Jiyu Li ◽  
...  
Tumor Biology ◽  
2015 ◽  
Vol 37 (1) ◽  
pp. 989-998 ◽  
Author(s):  
Siyuan Ma ◽  
Qingzhu Wang ◽  
Xiaojun Ma ◽  
Lina Wu ◽  
Feng Guo ◽  
...  

Thyroid ◽  
2016 ◽  
Vol 26 (12) ◽  
pp. 1733-1743 ◽  
Author(s):  
Shubin Hong ◽  
Shuang Yu ◽  
Jin Li ◽  
Yali Yin ◽  
Yujie Liu ◽  
...  

2016 ◽  
Vol 2016 ◽  
pp. 1-9 ◽  
Author(s):  
Huairong Zhang ◽  
Bo Gao ◽  
Bingyin Shi

Aim. We aim to identify protein kinases involved in the pathophysiology of papillary thyroid carcinoma (PTC) in order to provide potential therapeutic targets for kinase inhibitors and unfold possible molecular mechanisms.Materials and Methods. The gene expression profile of GSE27155 was analyzed to identify differentially expressed genes and mapped onto human protein kinases database. Correlation of kinases with PTC was addressed by systematic literature search, GO and KEGG pathway analysis.Results. The functional enrichment analysis indicated that “mitogen-activated protein kinases pathway” expression was extremely enriched, followed by “neurotrophin signaling pathway,” “focal adhesion,” and “GnRH signaling pathway.” MAPK, SRC, PDGFRa, ErbB, and EGFR were significantly regulated to correct these pathways. Kinases investigated by the literature on carcinoma were considered to be potential novel molecular therapeutic target in PTC and application of corresponding kinase inhibitors could be possible therapeutic tool.Conclusion. SRC, MAPK, and EGFR were the most important differentially expressed kinases in PTC. Combined inhibitors may have high efficacy in PTC treatment by targeting these kinases.


Sign in / Sign up

Export Citation Format

Share Document